Undifferentiated Gastric Carcinoma
NCI Definition: A carcinoma that arises from the stomach and is characterized by the absence of microscopic features of glandular or squamous differentiation. 
Undifferentiated gastric carcinomas most frequently harbor alterations in TP53, ZNF708, SMARCA4, RPTOR, and ROS1 .
ZNF708 Loss, TP53fs, TP53 c.217-c.1178 Missense, TP53 R282W, and TP53 Mutation are the most common alterations in undifferentiated gastric carcinoma .
There are 4 clinical trials for undifferentiated gastric carcinoma, of which 4 are open and 0 are completed or closed. Of the trials that contain undifferentiated gastric carcinoma as an inclusion criterion, 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open).
Paclitaxel, avelumab, and carboplatin are the most common interventions in undifferentiated gastric carcinoma clinical trials.
Significant Genes in Undifferentiated Gastric Carcinoma
CD274 is an inclusion eligibility criterion in 1 clinical trial for undifferentiated gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and undifferentiated gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.